Merkley Calls for FDA-Style AI Regulator

The policy stakes are material for the biggest names in AI because a tougher federal regime could raise compliance costs, slow product launches and create a clearer approval path for advanced models. Microsoft, Nvidia and other large AI players have already warned in filings that governments may restrict development or deployment based on safety, cybersecurity and legal concerns.

That makes the regulatory debate more than a political talking point. For investors, it affects the timing of product rollouts, the durability of AI-related revenue growth and the risk that new federal rules could compress margins across the sector if companies need more testing, documentation and oversight before shipping frontier models.

The discussion is unfolding as leading AI companies including Anthropic, OpenAI and Google separately work on a self-regulatory body aimed at setting safety standards, underscoring that the industry is trying to get ahead of lawmakers. It also comes as markets continue to reprice AI leaders against a backdrop of policy risk, with Nvidia’s shares recently at $222.27 and Microsoft at $493.78, both well above recent lows but still sensitive to any sign that regulation could slow the buildout.

Merkley’s proposal is likely to keep AI oversight on the agenda in Congress and the White House, where the next catalyst will be whether lawmakers move from broad warnings to a concrete framework for pre-market review, testing and enforcement.